Abstract Autoimmune diabetes has a heterogeneous phenotype. Although often considered a condition starting in childhood, a substantial proportion of type 1 diabetes presents in adult life. This holds important implications for our understanding of the factors that modify the rate of progression through the disease prodrome to clinical diabetes and for our management of the disease. When autoimmune diabetes develops in adulthood, insulin treatment is often not required at the time of diagnosis, and this autoimmune non-insulin requiring diabetes is generally termed latent autoimmune diabetes in adults (LADA). Patients with LADA are generally leaner, younger at diabetes onset; have a greater reduction in Cpeptide; and have a greater likelihood of insulin treatment as compared with patients with type 2 diabetes. The LADA subset of patients with adult-onset autoimmune diabetes has highlighted many shortcomings in the classification of diabetes and invokes the case for more personalized data analysis in line with the move towards precision medicine. Perhaps most importantly, the issues highlight our persistent failure to engage with the heterogeneity within the most common form of autoimmune diabetes, that is adult-onset type 1 diabetes, both insulin-dependent and initially non-insulin requiring (LADA).
Introduction
This review discusses characteristics of type 1 (autoimmune) diabetes and specifically aims to illustrate the heterogeneity of the disease. Critical to this analysis is the observation that a substantial proportion of type 1 diabetes (T1DM) presents in adult life, which has important implications for our management of the disease and our understanding of factors, which modify rates of progression through the disease prodrome to clinical diabetes.
Characteristics of Autoimmune Diseases
Type 1 diabetes is widely considered to be a chronic autoimmune disease caused by the interaction of genes and environment in which the genes are common variants of normal genes (and not gene mutations) and the environmental factors are unknown. The evidence that T1DM is an autoimmune disease is incomplete. Rose and Bona defined autoimmune diseases as those with three features: (i) the presence of defined autoantigens and autoantibodies, (ii) passive transfer of Tlymphocytes (specific or non-specific) must lead to disease development, and (iii) immunomodulation must ameliorate symptoms [1] . We know that the first of these is true and that the autoantibodies can predict the disease with a degree of certainty, notably the diabetes-associated antibodies (DAA) to glutamic acid decarboxylase (GADA), tyrosine phosphatase-like molecule (IA-2A), insulin islets (IAA), and zinc transporter 8 (ZnT8A) [2] . However, the second feature, transfer of disease, is ethically unacceptable, though a single case has been described of apparent transfer of T1DM following a bone marrow transplant from a diabetic donor to a non-diabetic recipient [3] . The third feature has not yet been met since no immunomodulation therapy has had sufficient impact to restore normal glucose homeostasis permanently. However, a number of studies have illustrated transiently improved insulin secretion with immunomodulatory therapy (e.g., cyclosporin, anti-CD3, and abatacept), using C-peptide as a proxy of insulin secretion [4] . This lack of clarity regarding the extent to which T1DM is an autoimmune disease has led to it being considered a partly autoimmune disease or an autoinflammatory disease, a disease initiated by an environmental insult which damages islet cells that is augmented by autoimmune features in those with genetic susceptibility [5] .
Genetic susceptibility to autoimmune disease is broadly associated with human leukocyte antigen (HLA) variants. However, these variants differ, even at a given locus, and the same allele often has divergent protective or risk associations across autoimmune diseases [6, 7] . Notably, risk alleles with the largest effects are frequently disease-specific. Nevertheless, HLA risk variants are invariably linked to the immune response, specifically to the presentation and response of Tcells to an antigen presented by an antigen presenting cell (APC) as the HLA variants determine the structure and charge of surface cleft pockets for binding APC-derived peptides and thus the affinity and presentation of antigens to thymocytes in the thymus and peripherally.
Non-genetically determined factors are likely to be environmental factors. The majority of identical twins with an autoimmune disease have an unaffected twin, i.e., they are discordant for the disease. Differences between identical twins are likely to be non-genetically determined. However, even identical twins can differ genetically, e.g., methylation of CpG sites may be associated with altered transcription [8] . Thus, discordance between identical twins may be determined by non-genetic factors operating on genetic expression. However, if a somatic mutation of the immune system caused autoimmune disease, the aberrant immune response would probably be monoclonal and not polyclonal as is the case in common autoimmune diseases [9] . We therefore believe, though we cannot be certain, that common autoimmune diseases are partly due to an environmental agent(s) and not a somatic mutation. It remains possible, even likely, that different environmental factors operate at different stages in the progression from birth to tissue inflammation to tissue destruction and clinical disease.
Three features are held to characterize the adverse immune response in autoimmune diseases. First, the immune response, once activated, probably launches an adverse T-cell mediated target organ-specific immune response. Second, the immune responses would need to be proinflammatory and not antiinflammatory. Third, the immune response that normally regulates autoimmunity must fail, if we assume the destruction is autoimmune. The complex mechanisms causing loss of immune self-tolerance involves multiple aspects of adaptive immunity, including activation of the innate immune system which sets the stage for an adverse effect-a theory considered in the hygiene hypothesis [5] . The immune system encompasses an innate and an adaptive arm in which the innate system response remains unaltered if repeatedly challenged, whereas the adaptive system develops and expands that response. The innate system activates the adaptive system via APCs when a challenge is encountered. Interactions between the two systems via humoral and cellular responses determine the immune response outcome [10] . In autoimmune diabetes, there is substantial evidence that innate immunity is deranged [11] [12] [13] [14] .
Autoreactivity is curtailed by both central and peripheral mechanisms. Immature T-cells (thymocytes) are exposed to self-peptides by APCs in the thymus. Only thymocytes with low affinity for autoantigens are selected positively and released to peripheral circulation, whereas high affinity leads to negative selection. Even so, autoreactive elements may be found in the peripheral circulation in all healthy individualsbut further peripheral counter regulation in the spleen and lymph nodes (by deletion, anergy, ignorance, and by regulatory T-cells) serves to curtail self-reactivity. Regulatory T-cells migrate from the thymus to periphery to neutralize autoreactive T-cells that escaped thymic deletion. Deficiency of naturally occurring regulatory Foxp4 + CD4 + T-lymphocytes-which mediate self-tolerance-contributes to development of autoimmune diabetes by impaired suppression of diabetogenic T-cell differentiation [15] .
Features of Autoimmune Diabetes Relative to Other Autoimmune Disease
Twin studies in autoimmune diseases indicate increased concordance rates in identical twins compared with non-identical twins consistent with a strong genetic effect. However, concordance is short of 100 % consistency with a role for nongenetic effects [16] .
Epidemiological studies have established that the risk of developing autoimmune diseases has increased substantially in recent years consistent with some common exposure to non-genetic effects that lead to a range of immune-mediated diseases including T1DM and asthma. The potential role of shared environment has only recently been highlighted [17] .
Age and cohabitation shape the cellular composition of the human immune system [17] . Non-genetic factors associated with autoimmune diseases include the following: gluten (for coeliac disease); smoking (in rheumatoid arthritis, systemic lupus erythematosus although protective against T1DM for offspring of smoking mothers); periodontal disease (in rheumatoid arthritis); iodine deficiency (autoimmune thyroid disease); and hair dyes-which are tyrosine mimetics (vitiligo) and oral female hormone replacement (primary biliary sclerosis). There are many factors with a less-certain association including sunlight exposure (possibly multiple sclerosis, T1DM) and viruses (T1DM, multiple sclerosis, thyroid disease, and inflammatory bowel disease).
The majority of autoimmune diseases are more prevalent in women and in middle-aged patients. There are, however, exceptions and among these is T1DM which is prevalent in childhood. Diseases such as T1DM, thyrotoxicosis, and psoriasis tend to be more severe when diagnosed in childhood than in middle age. Indeed, a striking feature of most autoimmune disease is the broad clinical phenotypic variation ranging from severe disease to no clinical disease. A classic example is Hashimoto's thyroiditis, which can affect some 10 % of the adult population yet only 1 % of the population have clinically treated hypothyroidism [18] .
Characteristics of Autoimmune Diabetes and How They Are Similar or Differ From Type 2 Diabetes
T1DM and type 2 diabetes (T2DM) both show a decline in beta-cell function, low beta-cell mass, increased beta-cell stress, and altered lipidomics. T1DM, in addition, is characterized by a striking association with HLA-complex genes, the presence of DAA, and pronounced loss of insulin secretion capacity. However, there is striking heterogeneity within both T1DM and T2DM. This heterogeneity encompasses the age at onset of T1DM, so that while the majority present in adulthood in line with other autoimmune diseases, a sizable proportion develops the disease in childhood. When autoimmune diabetes develops in adulthood, insulin treatment is usually not required at the time of diagnosis, and this autoimmune non-insulin requiring diabetes is generally termed latent autoimmune diabetes in adults (LADA). LADA is conventionally defined by age at diagnosis, autoantibody positivity, and timing of need for insulin treatment. This condition challenges the current diabetes classification system as evidenced by the lack of a common definition by the leading diabetes organizations [19••] . Definitions of an adult-onset range in LADA from older than 15 years upwards to more than 30 years of age, and the antibody criteria are not specific for LADA, as they are based on autoantibodies associated with childhoodonset T1DM, i.e., GADA, IA-2A, IAA, and ZnT8A. In the absence of ketoacidosis, the decision to start insulin treatment depends on the clinician's preference and hence, this criterion confers additional uncertainty to the diagnosis of LADA. Even though no general consensus has been established, many designate DAA positive patients >30 years of age without insulin-requirement for at least 6 months after diagnosis as having LADA [20, 21] .
Epidemiology
Several studies have shown that a significant proportion of initially non-insulin requiring adult patients are incorrectly diagnosed with T2DM as they have DAA and could be reclassified as LADA. A high frequency (7-14 %) has been observed in studies from northern Europe [22•, 23, 24, 25 ••], potentially higher compared to studies from southern Europe, Asia, and North America (4-6 %) [26-28, 29••, 30] and the Middle East (2.6 %) [31] . Two recent studies have evaluated the prevalence of LADA as compared with classic T1DM in adult-onset autoimmune diabetes. The Action LADA 7 study including 6156 adult-onset (age at diagnosis 30-70 years) patients with diabetes from nine European countries identified adult-onset autoimmune diabetes in 598 patients (9.7 %). Within the DAA positive patients, LADA (defined as patients who did not require insulin treatment for at least 6 months post-diagnosis) was more prevalent (6.1 %) than classic T1DM (insulin started at diagnosis; 1.9 %) [32••] . In 17,072 patients with adult-onset diabetes from the United Arab Emirates, DAA positivity was identified in 471 (2.8 %) patients. Four hundred thirty-seven patients (2.6 %) were identified as having LADA (defined as patients who did not require insulin treatment for at least 6 months postdiagnosis) and 34 patients (0.2 %) as having T1DM (defined as start of insulin treatment <6 months post-diagnosis) [31] . Both studies thus implicate LADA as the most prevalent form of autoimmune diabetes in adults.
Genetics
LADA may share genetic characteristics with both T1DM and T2DM. The common variant in the transcription factor 7-like 2 (TCF7L2) rs7903146 (CT/TT genotypes) has showed strong association with T2DM [33, 34] and the same risk variant was associated with LADA, but not classical T1DM [35, 36•, 37] ; importantly, these studies are small and need to be validated. On the other hand, classical T1DM and patients with LADA are associated with several of the same major histocompatibility complex MHC II genotypes, e.g., positively associated with the DRB1*04-DQB1*0302 (DR4/DQ8) haplotype and negatively associated with the DRB1*11-DQB1*0301 haplotype, even though they differ in other HLA loci [38, 39••] . HLA-DRB1*03/HLA-DRB1*04 (DR3/4) genotypes has been associated with age at diagnosis, with lower DR3/4 frequency seen in older age, in both childhood-onset diabetes and LADA [38, 40, 41] and presence of high-risk HLA genotypes for T1DM correlated with rate of progression to insulin therapy in patients with LADA [28] . Childhood-onset diabetes and LADA has also been associated with the same non-HLA genes, with the strongest association observed for INS and PTPN22, followed by STAT4, CTLA4, IL2RA, ERBB3, SH2B3, and CLEC16A [42] . The slower progression of beta-cell loss seen in LADA as compared to classical T1DM may reflect minor MHC-class variations, lower overall genetic load, and less genetic penetrance implicating a relatively larger impact of environmental factors [21, 42] . The data suggest LADA represents a genetic form of classic T1DM, but genes associated with T2DM could still play a role. Whether this genetic background implicates LADA is a distinct disease entity or part of a continuum remains debated.
Characteristics of the Immune system in Autoimmune Diabetes
Although beta-cell loss in autoimmune diabetes is largely driven by the cellular arm of the immune system, detection of circulating DAA is used to discriminate it from nonimmune diabetes. By definition, both LADA and classic T1DM are characterized by the presence of autoantibodies. Similar autoantibodies are seen in patients with LADA and T1DM, e.g., GADA, IAA, IA-2A, and ZnTn8 [25••, 43, 44] . In the United Kingdom Prospective Diabetes Study (UKPDS) cohort, antibodies against GAD, IA-2, and IC were present in about 11 % of participants [44] . Multiple studies describe fluctuating autoantibody positivity associated with disease progression [45] [46] [47] . In addition, antibody composition may predict disease severity (e.g., patients with high GADA titers have more severe disease and a greater need of insulin supplementation) [25••, 48] .
Ascertainment of cellular immune reaction is complicated by the need for pancreas biopsy which hinders the detection of early-stage insulitis. Recently, a non-invasive positron emission tomography-based technique has been described exploiting the binding of interleukin-2 (IL-2) to activated lymphocytes [49] . The study demonstrated an increased pancreatic uptake of labeled IL-2 in autoimmune diabetes especially close to diagnosis and in LADA. An interesting approach to a cellular detection of autoimmunity in diabetes has been described by Brooks-Worrell and colleagues [50] [51] [52] . By detection of reactivity of peripheral blood mononuclear cells (PMNC) towards proteins from pancreatic islets, the assay identifies patients with autoimmune diabetes with high sensitivity and specificity as compared with controls. These autoreactive PMNCs are interestingly also observed in patients clinically categorized as having T2DM, but the targets proteins seem to differ from patients with T1DM [51, 53•] . This study needs to be confirmed but it raises many questions beyond the scope of this article regarding the extent of autoimmunity in both major types of diabetes.
Recently, the distribution of B-lymphocyte subpopulations has been compared in adult autoimmune diabetes, T1DM, T2DM, and healthy controls. The subpopulation distribution differs among these groups and was correlated with clinical characteristics, e.g., blood pressure and body mass index (BMI) [54] .
Changes in islets of patients with autoimmune diabetes also support this underlying heterogeneity. For example, islets may contain CD8 positive cells irrespective of age at diagnosis, but the CD20 + B cells do vary so that young onset disease (age 0-6 years) tend to show substantial hyperimmune CD20 + (CD20Hi) expression but with few insulin-positive cells, while those aged more than 13 years at diagnosis show pauci-immune CD20 + (CD20Lo) expression but with many insulin-positive cells [55] . In a related study, it was noted that patients showed distinct peripheral blood immune agglomerations characterized by proinflammatory (interferon-γ-positive, multi-autoantibody-positive) or partially regulated (IL-10-positive, pauci-autoantibody-positive) responses in which the former were diagnosed at a younger age than the latter [56••] . These histological and peripheral blood changes correspond to two endotypes in T1DM, a young age at onset multiple antibody-positive aggressive tissue destruction associated with HLA DR 4, DQ8 and the other associated with a single autoantibody (invariably GADA), older age at onset, HLA DR3, DQ2 and less severe insulin secretory dysfunction.
Clinical Features
Patients with adult-onset autoimmune diabetes (when characterized as LADA) are generally leaner, younger at diabetes onset, have a greater reduction in C-peptide levels, and have a greater likelihood of insulin treatment as compared with patients with type 2 diabetes [23, 29••, 32••]. However, the clinical phenotype within patients with LADA varies substantially with GADA titer. Patients with low GADA titer are phenotypically more similar to patients with T2DM with a higher prevalence of the metabolic syndrome and lower rate of progression to insulin treatment as compared to patients with high GADA titer, who are more akin to patients with classic T1DM [23, 24, 26, 29••, 32••] . Even so, the clinical features overlap considerably and individual patients with LADA cannot be distinguished from patients with T2DM based on clinical features [57, 58] . Hence, LADA shares characteristics of both T1DM and T2DM as illustrated in Fig. 1 .
Metabolic Phenotype
Histological data suggests an age-dependent rate of disease progression, as beta cells tend to be absent within 12 months of diagnosis in patients aged less than 7 years, but detectable for longer periods in older patients [59] . Variability in progression to clinically overt diabetes can even be detected in very young children; for example, of children identified between 1 and 5 years of age with DAA and subnormal insulin responses, approximately 50 % progress rapidly to diabetes while the remainders are free from diabetes up to 4 years later [60] . Other studies have noted such variable progression to T1DM, which is more rapid in obese than lean children and in children than adults [61] [62] [63] . In the same way, there is heterogeneity in islet cell growth and this might account for the prolonged and slow progression in adolescence to frank T1DM.
From these observations, it follows that there is a spectrum in the rate of metabolic de-compensation during the prediabetic period in T1DM, but no data is available, as yet, in LADA. GADA-positive patients with LADA, as compared to GADA-negative patients with T2DM, had a lower fasting Cpeptide concentration and triglyceride level and a higher HDL cholesterol level [24] . Similarly, insulin-treated patients with LADA in the Nord-Trøndelag Health Study (the HUNT study) had higher GADA titers and lower fasting C-peptide concentration as compared with patients with LADA without insulin treatment [23] .
GADA-positive patients have lower frequency of metabolic syndrome and lower C-peptide than GADA-negative patients and among GADA-positive patients with LADA, hightiter patients have lower frequency of metabolic syndrome, and lower C-peptide levels as compared with low-titer patients [24, 26, 29••, 30, 32••, 64] . However, significant overlaps between the groups were observed. In the A Diabetes Outcome Progression Trial (ADOPT), GADA-positive patients diagnosed as having T2DM had higher insulin sensitivity as compared with GADA-negative patients with T2DM [30] . When adjusting insulin response to oral glucose stimulation for difference in insulin sensitivity, beta-cell function did not differ between the two groups [30] . This observation is in agreement with other studies [65, 66] . Longitudinal data from the UKPDS and from a recent Chinese study are informative. In the UKPDS, 84 % of the patients with GADA and 94 % of those with ICA initiated insulin treatment during 6 years of follow-up as opposed to only 14 % of the ICA and GADA-negative patients [25••] . Huang and co-authors found that patients with LADA persistently positive for GADA had the fastest declining C-peptide levels as compared to patients with transient or fluctuating GADA positivity or T2DM patients [46] . Huang et al. further reported GADA-positive patients to have higher HbA 1c as compared with T2DM patients, and this feature is common to most studies of these two forms of diabetes [46] .
Conclusions: How Classification of Adult-Onset Patients Impacts Therapy
It is our opinion that presence of DAA in patients with noninsulin requiring diabetes identifies a form of autoimmune diabetes, especially in adults, which is (1) often inappropriately treated, (2) requires distinct therapy, (3) requires more frequent monitoring in the clinical setting, and (4) demands a different perspective in terms of co-morbidities.
Choice of treatment strategy in patients with LADA is challenged by the scarcity of randomized controlled trials. The available evidence indicates that patients with autoimmune non-insulin-requiring diabetes with glycemic dysregulation should be started on insulin or an incretinbased therapy or, potentially, a combination of the two [67, 68] , as suggested by a phase 2 study of adult patients with autoimmune diabetes in which the gliptin plus insulin combination sustained C-peptide better than insulin alone [69] .
Metformin is widely prescribed, yet there are no controlled trials of metformin alone in LADA and accordingly, no evidence for or against metformin. Sulfonylurea treatment, however, is discouraged, as patients on this class of drugs have a faster loss of insulin secretory capacity than when treated with insulin [70] . Controlled trials to define best therapy for LADA are urgently required.
The presence of autoimmunity does not necessarily require the use of insulin therapy. Although patients with classical T1DM presenting with ketoacidosis require immediate insulin therapy, not all patients with adult-onset autoimmune diabetes such as LADA, need progress to insulin therapy; as illustrated by a recent study, in which 44 % were still not on insulin after 12 years of disease [22• Fig. 1 Homo diabeticus illustrating the continua of disease-associated factors across the range of diabetic phenotypes. Variable combinations of disease-associated characteristics are observed according to diabetes type for obesity (body mass index), influence of adaptive immunity and immune genes, and level of insulin secretion and insulin sensitivity. BMI body mass index, LADA latent autoimmune diabetes of the adult, GADA glutamic acid decarboxylase antibody, HLA human leukocyte antigen. To be validated: TCF7L2; transcription factor 7-like 2 gene patients [71] . Accordingly, patients with LADA seem less well managed than non-insulin requiring non-autoimmune diabetes patients (i.e., T2DM).
Microvascular complications are generally observed with comparable frequency in LADA as in patients with T2DM [22•, 73-75] . Despite a more favorable cardiovascular risk profile (e.g., lower BMI) in LADA, the available evidence does not indicate lower incidence of cardiovascular disease [22•, 73, 74] . Thus, the data indicate that treatment of cardiovascular risk factors should not be less aggressive in LADA as compared to non-autoimmune diabetes (i.e., T2DM).
Finally, patients with autoimmune diabetes including LADA are at considerably increased risk of thyroid and parietal cell autoimmunity leading to pernicious anemia [26, 72] . The presence of DAA should encourage regular review of comorbidities. Complication risk factors will likely vary in adult-onset T1DM as compared with T2DM. In due course, targeted therapy will be required for patients with autoimmune diabetes to include specific drug combinations, potentially extending to immunomodulation. In that case, the age at onset may impact the therapy, e.g., the beneficial rituximab (anti-B-cell therapy) response in T1DM was driven by children without any beneficial effect on C-peptide secretion in adults [76] .
The LADA subset of patients with adult-onset autoimmune diabetes has highlighted many shortcomings in the classification of diabetes and invokes the case for more personalized data analysis in line with the move towards precision medicine. At the beginning of this analysis, we considered whether T1DM was, indeed, an autoimmune disease, an autoinflammatory disease, or a disease due to an initial environmental insult, which induces autoimmune damage. The evidence raises the prospect that all these features could operate to different degrees at different ages of onset. Perhaps most importantly, the issues highlight our persistent failure to engage with the heterogeneity within the most common form of autoimmune diabetes, that is adult-onset T1DM, both insulin-dependent and initially non-insulin requiring (LADA). Underlying these issues is the intriguing question as to why the severity of loss of insulin secretion in T1DM is so variable. The answer may illuminate the origins and prevention of this autoimmune disease.
